Sinopharm Group CoSHTDF -2.67%78 PE Ratio (TTM) is 7.08 as of Jun. 24, 2026, which is 13% below its 10-year median of 8.17. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 89 Medical Distribution companies, Sinopharm Group Co ranks better than 95.51% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-24), Sinopharm Group Co's share price is
$2.2872.
Sinopharm Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.32. Therefore, Sinopharm Group Co's PE Ratio (TTM) for today is 7.08.
Good Sign:
Sinopharm Group Co Ltd stock PE Ratio (=6.23) is close to 1-year low of 6.16.
The historical rank and industry rank for Sinopharm Group Co's PE Ratio (TTM) or its related term are showing as below:
SHTDF'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 4.8 Med: 8.17 Max: 25.67
Current: 6.26
During the past 13 years, the highest PE Ratio (TTM) of Sinopharm Group Co was 25.67. The lowest was 4.80. And the median was 8.17.
SHTDF's PE Ratio (TTM) is ranked better than 95.51% of 89
companies
in the Medical Distribution industry
Industry Median: 16.15
vs SHTDF: 6.26
During the past 12 months, Sinopharm Group Co's average EPS without NRIGrowth Rate was -4.90% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -6.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -3.30% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 7.20% per year.
During the past 13 years, Sinopharm Group Co's highest 3-Year average EPS without NRI Growth Rate was 115.70% per year. The lowest was -6.40% per year. And the median was 17.10% per year.
Sinopharm Group Co's EPS (Basic) for the
six
months ended in Dec. 2025 was $0.17.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.32.
Sinopharm Group Co (OTCPK:SHTDF) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Sinopharm Group Co PE Ratio (TTM) Related Terms
Sinopharm Group Co PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co PE Ratio (TTM) vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Sinopharm Group Co's Share Price of today is $2.2872.
For company reported semi-annually, Sinopharm Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Sinopharm Group Co (SHTDF) has a PE Ratio (TTM) of 7.08 as of Jun. 24, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Sinopharm Group Co and its competitors. This is 13% below median its historical median of 8.17. Over the past decade, Sinopharm Group Co's PE Ratio (TTM) has ranged from 4.80 to 25.67. According to the industry distribution chart, Sinopharm Group Co ranks #4 out of 89 companies in the Medical Distribution industry, placing it in the top 4.5%.
Is Sinopharm Group Co's PE Ratio (TTM) too high?
Sinopharm Group Co's current PE Ratio (TTM) of 7.08 is 13% below median its 10-year median of 8.17. Over the past 10 years, this metric has ranged from a low of 4.80 to a high of 25.67. The Medical Distribution industry median PE Ratio (TTM) is 16.15. Sinopharm Group Co's value of 7.08 is 56.2% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #4 out of 89 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's PE Ratio (TTM) compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #4 out of 89 companies for PE Ratio (TTM). This places Sinopharm Group Co in the top 5% of its industry — outperforming the majority of peers. The industry median PE Ratio (TTM) is 16.15. Sinopharm Group Co's value of 7.08 is 56.2% below this benchmark. Historically, Sinopharm Group Co's own PE Ratio (TTM) has ranged from 4.80 to 25.67 over the past decade. While the company's 10-year median is 8.17 vs. the industry median of 16.15, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Distribution company?
The median PE Ratio (TTM) among Medical Distribution companies is 16.15, based on 89 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current PE Ratio (TTM) of 7.08 is 56.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median PE Ratio (TTM) is 16.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current PE Ratio (TTM) is 7.08, which is 13% below median its own 10-year median of 8.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current PE Ratio (TTM) is 7.08, which is 13% below median its 10-year median of 8.17 and 56.2% below the Medical Distribution industry median of 16.15. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current PE Ratio (TTM) is 7.08 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
PE Ratio (TTM): 7.08 (13% below median its 10-year median of 8.17)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 56.2% below the Medical Distribution median (#4 of 89)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
